Has Ed Sheeran said he uses Ozempic or any GLP-1 drug?

No. As of May 2025, Sheeran has made no public statement confirming the use of semaglutide, tirzepatide, or any GLP-1 receptor agonist. His public comments attribute his weight loss to exercise and diet changes.

Can you lose significant weight just by quitting alcohol and exercising?

Yes. Alcohol is calorically dense (roughly 7 kcal per gram, plus mixers and food consumed alongside it). A person drinking 4 to 6 beers daily who stops eliminates 600 to 1,200 calories per day. Combined with 30 to 60 minutes of daily running (burning approximately 300 to 600 kcal depending on pace and body weight), total daily deficit can reach 1,000 to 1,800 kcal, producing 2 to 3 pounds of weekly fat loss.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (doses up to 2.0 mg weekly). Wegovy is approved for chronic weight management (dose of 2.4 mg weekly). The active molecule is identical; the approved indication, dosing schedule, and insurance coverage differ.

Do GLP-1 drugs cause muscle loss?

Weight lost on GLP-1 agonists includes both fat and lean mass. In clinical trials without structured resistance training, approximately 25 to 40% of weight lost was lean mass. Concurrent resistance exercise appears to improve this ratio, though dedicated trial data on exercise plus GLP-1 therapy are still emerging.

Why do people speculate about celebrity GLP-1 use?

The rapid rise in GLP-1 prescriptions (semaglutide prescriptions increased over 300% between 2020 and 2023) coincided with visible weight loss in many public figures. Media and social platforms often attribute any notable physical change during this period to these medications, regardless of individual circumstances.

Ed Sheeran Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Ed Sheeran Transformation Timeline: Public Photos, Public Statements, and the Medical Context Image: HealthRX.com clinical image

The Public Record: What Ed Sheeran Has Actually Said

Ed Sheeran's relationship with his own weight has been part of his public narrative for years. In a 2022 interview, Sheeran discussed gaining weight during the pandemic period and his subsequent commitment to running and cutting back on alcohol. He told interviewers that daily exercise and reduced caloric intake were central to the change.

No interview, social media post, or on-record statement from Sheeran has referenced semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or any other GLP-1 receptor agonist. The speculation exists almost entirely in tabloid coverage and social media commentary, fueled by the timing of his visible physical changes coinciding with the broader cultural wave of GLP-1 prescriptions rising sharply in 2022 and 2023.

This distinction matters. Public figures are not obligated to disclose medical treatments, and visible weight loss alone is not evidence of pharmaceutical intervention.

Timeline of Publicly Documented Changes

2019 to 2021: The Touring and Pandemic Phase

During his Divide Tour (2017 to 2019), Sheeran spoke openly about the excesses of touring life. He referenced heavy drinking, late-night eating, and minimal structured exercise. Photos from late 2019 and through 2020 show a heavier build consistent with his own descriptions.

The pandemic period brought a pause from touring. Sheeran has spoken about using this time with family, and public photos from 2020 to 2021 show relatively stable body composition.

2022: Visible Shift

By mid-2022, public appearances and paparazzi photos showed a noticeably leaner Sheeran. He discussed running as a daily habit and mentioned cutting beer consumption significantly. These statements appeared across multiple outlets and were consistent in their framing: lifestyle-driven changes, not medical intervention.

From a clinical standpoint, the rate and degree of change visible in Sheeran's public photos are consistent with what exercise physiologists would expect from a male in his early 30s who adopts regular cardiovascular exercise and reduces alcohol intake. A man consuming 4 to 6 beers daily who stops can eliminate 600 to 1,200 kcal per day, a deficit sufficient for 1 to 2 pounds of fat loss per week without any other intervention (NIAAA caloric data).

2023 to 2024: Sustained Change and Renewed Speculation

Sheeran's leaner appearance persisted through the Mathematics Tour (2023 to 2024). Tabloid outlets and social media users speculated about GLP-1 use, often citing the "Ozempic era" framing applied broadly to any public figure who lost weight during this period.

Sheeran did not address these rumors directly. His public comments continued to reference exercise and diet.

Clinical Context: What GLP-1 Receptor Agonists Actually Do

Regardless of whether Sheeran has used a GLP-1 agonist, the public conversation around his weight loss offers a useful entry point for understanding these drugs.

GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1. They slow gastric emptying, increase insulin secretion in a glucose-dependent manner, and act on hypothalamic appetite centers to reduce hunger. The two most prescribed agents for weight management are semaglutide (branded as Wegovy for obesity, Ozempic for type 2 diabetes) and tirzepatide (Mounjaro, Zepbound), which also activates GIP receptors.

Expected Weight Loss in Clinical Trials

In the STEP 1 trial, adults without diabetes receiving semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM 2021). The SURMOUNT-1 trial showed tirzepatide at the highest dose (15 mg) produced 22.5% mean weight loss over 72 weeks (Jastreboff et al., NEJM 2022).

These are population averages. Individual responses vary widely. Some patients lose 5%; others exceed 25%.

Side Effect Profile

The most common adverse effects are gastrointestinal: nausea (reported in 40 to 44% of semaglutide patients in STEP trials), vomiting, diarrhea, and constipation. These tend to be dose-dependent and often diminish after the first 8 to 12 weeks. More serious but rarer risks include pancreatitis, gallbladder disease, and potential thyroid C-cell concerns observed in rodent models (boxed warning on all GLP-1 RA labels per FDA prescribing information).

The Muscle Mass Question

One clinical concern especially relevant to male patients is lean mass loss. Weight lost on GLP-1 agonists is roughly 60 to 75% fat mass and 25 to 40% lean mass in trials without concurrent resistance training (Wilding et al., NEJM 2021). For a physically active man like Sheeran, who has described regular exercise, the lean-mass preservation profile would differ from that of a sedentary patient. Resistance training during GLP-1 therapy can shift the ratio toward greater fat loss and less muscle loss, though head-to-head data on this specific question remain limited.

Why the Speculation Follows This Pattern

The HealthRX.com Medical Team notes a recurring pattern in male celebrity weight-loss coverage. When a man in public life loses visible weight, speculation about pharmaceutical assistance tends to follow a predictable arc: initial tabloid reports, social media amplification, and then a binary framing (either the person "admits" to using a drug or they are assumed to be hiding it).

This framing obscures the clinical reality. Weight loss occurs on a spectrum of interventions: caloric restriction alone, exercise alone, behavioral therapy, pharmacotherapy, bariatric surgery, or combinations. A person can lose 30 pounds through running and quitting beer. A person can also lose 30 pounds on semaglutide. The visual result can look identical.

The more productive question is not "is this person on Ozempic?" but rather "what does the clinical evidence say about the methods available, and how do outcomes compare?"

At a glance

Has Ed Sheeran confirmed GLP-1 use? No. He has not publicly confirmed using any GLP-1 receptor agonist.
What has he attributed his weight loss to? Exercise (primarily running) and dietary changes, including reduced alcohol intake.
Could lifestyle changes alone explain the visible change? Yes. The degree of change documented in public photos is consistent with regular cardio and alcohol cessation in a male in his early 30s.
What are GLP-1 agonists prescribed for? Chronic weight management (BMI ≥ 30 or ≥ 27 with a weight-related comorbidity) and type 2 diabetes.
What weight loss do GLP-1 drugs produce? Mean losses of 15 to 22.5% body weight over 68 to 72 weeks in clinical trials.

The HealthRX.com Medical Team Take

We cannot and do not speculate on Ed Sheeran's private medical decisions. What we can say is this: the public record supports the explanation Sheeran has given. A man in his early 30s who begins daily cardiovascular exercise and eliminates significant alcohol calories can achieve meaningful, sustained weight loss without pharmaceutical assistance.

If Sheeran or any similarly situated patient were considering a GLP-1 agonist, the clinical conversation would center on BMI thresholds (FDA criteria require BMI ≥ 30 or ≥ 27 with comorbidity), cardiovascular risk reduction (the SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide), and the practical reality of long-term adherence. These drugs work while you take them. Discontinuation leads to weight regain in most patients, with roughly two-thirds of lost weight returning within a year of stopping.

The broader lesson: public speculation about celebrity drug use tells us more about cultural anxiety around weight loss than it does about any individual's medical choices.

Frequently asked questions

›

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
FDA. Highlights of prescribing information: Wegovy (semaglutide). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
CDC. Alcohol and public health: moderate drinking. https://www.cdc.gov/alcohol/fact-sheets/moderate-drinking.htm